Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: Oct 21, 2025 · CIK: 1590750
| Field | Detail |
|---|---|
| Company | Viridian Therapeutics, Inc.\De (VRDN) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $490.9 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations-update
TL;DR
Viridian Therapeutics (VRDN) filed an 8-K on Oct 21, 2025, updating on financial condition.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on October 21, 2025, reporting on its results of operations and financial condition. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing provides an update on Viridian Therapeutics' financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on financial condition, not a material event like a merger or significant product update.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Principal business address
FAQ
What is the primary purpose of this 8-K filing for Viridian Therapeutics?
The primary purpose is to report on the company's results of operations and financial condition as of October 21, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 21, 2025.
What were Viridian Therapeutics' previous company names?
Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
In which state is Viridian Therapeutics incorporated?
Viridian Therapeutics is incorporated in Delaware.
What is the principal business address of Viridian Therapeutics?
The principal business address is 221 Crescent Street, Suite 103A, Waltham, MA 02453.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 13.8 · Accepted 2025-10-21 16:35:06
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
- $490.9 million — cts to report that it had approximately $490.9 million of cash, cash equivalents and marketabl
Filing Documents
- d12120d8k.htm (8-K) — 24KB
- g12120g1021025336233.jpg (GRAPHIC) — 3KB
- 0001193125-25-245206.txt ( ) — 142KB
- vrdn-20251021.xsd (EX-101.SCH) — 3KB
- vrdn-20251021_lab.xml (EX-101.LAB) — 18KB
- vrdn-20251021_pre.xml (EX-101.PRE) — 11KB
- d12120d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: October 21, 2025 By: /s/ Stephen Mahoney Stephen Mahoney President and Chief Executive Officer